Rapport Therapeutics, Inc. RAPP
27.02 USD +1.06 (+4.08%)
At closeNov 11, 2026, 7:25 PM EST
26.49 -0.53 -1.97%
After hours · Nov 11, 7:25 PM ET
25.77 Day range 27.10
22.06 52-week range 52.93
- YTD
- -10.94%
- 1 year
- +5.96%
News
investorplace.com Insider Buying Signals: 3 Healthcare Stocks to Watch Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
benzinga.com UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 UBS analyst Joon Lee maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $71 to $64.- benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.
benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.
benzinga.com Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.19) by 29.41 percent. This is a 18.31 percent decrease over losses…
globenewswire.com Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label long-term safety…
globenewswire.com Rapport Therapeutics to Participate in Upcoming Investor Conferences BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…- benzinga.com Rapport Therapeutics Closes Underwritten Public Offerings Of 9,761,905 Shares At $21.00 Per Share Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
globenewswire.com Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
benzinga.com Enphase Energy Posts Downbeat Q3 Results, Joins NXP Semiconductors, Seagate And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed as Enphase plunges 17% after earnings and weak guidance; Rapport, Intapp, Logitech and others also fall premarket.
benzinga.com Rapport Therapeutics Prices Separate Offerings Of ~$175M Of Stock At $21.00/Share, Warrants To Purchase Up To ~$25M Of Stock At $20.999 Per Pre-Funded Warrant, And $150M Of 2.25% Convertible Senior Notes Due 2032 Concurrently with the underwritten offerings, Rapport entered into a share purchase agreement with a certain investor (the "Investor"), in a separately negotiated transaction (the "concurrent private
globenewswire.com Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement BOSTON and SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
benzinga.com Why Ultra Clean Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Ultra Clean shares surged 14.6% after beating earnings and sales estimates; Ultralife soared 143.8% on a $320M acquisition deal.
benzinga.com Rapport Therapeutics (RAPP) Shares Sink 20% After Hours Rapport Therapeutics stock falls after hours as investors assess proposed stock and convertible notes offerings.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
- benzinga.com Rapp Therapeutics Files For Offering Of Common Stock; Size Not Disclosed Common StockWe are offering $ of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.Our common stock is listed on The Nasdaq Global Market under the…
- benzinga.com Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for…
globenewswire.com Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
defenseworld.net Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stock Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction dated Wednesday, October 21st. The shares were sold at…
marketbeat.com Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial Rapport Therapeutics NASDAQ: RAPP reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary…- benzinga.com Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82 Jones Trading analyst Justin Walsh maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $50 to $82.
- benzinga.com Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50 Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $51 to $50.
benzinga.com Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70 Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.
seekingalpha.com Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
benzinga.com HC Wainwright & Co. Reiterates Buy on Rapport Therapeutics, Maintains $66 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $66 price target.
benzinga.com Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro…
benzinga.com Why Is Rapport Therapeutics Stock Trading Higher Today? Rapport Therapeutics posts positive Phase 2 trial results for RAP-219 in acute bipolar mania, setting up Phase 3 studies in 2027.
barrons.com Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $75 to $89.- benzinga.com Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…
globenewswire.com Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
- benzinga.com UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71 UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.
- benzinga.com Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50 Wolfe Research initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $50.
benzinga.com Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65 Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
seekingalpha.com Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up…
seekingalpha.com Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
zacks.com 4 Biotech Stocks With Key Clinical Readouts Expected This Fall KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.- benzinga.com BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75 BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
defenseworld.net Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP Legal and General Group Plc acquired a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent filing with the…
globenewswire.com Rapport Therapeutics to Participate in Upcoming Investor Conferences BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and…
defenseworld.net Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent 13F filing with the…
defenseworld.net Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent disclosure with the SEC.…- benzinga.com BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66 HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.